Lanzamiento Enero 2027

Estudio2014Solo mecanismosAcceso abierto

Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells

Wong CP, Hsu A, Buchanan A, Palomera-Sanchez Z, Beaver LM, Houseman EA, Williams DE, Dashwood RH, Ho E

PloS one · 76 citas

Etiquetas de revisión

Solo mecanismos

Datos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.

Cómo se estudió

Diseño
Estudio in vitro o de mecanismos (clasificado por nuestro filtro de IA)
Estudiado en
Células o muestras de laboratorio
Resultado principal
Solo mecanismos

Quién lo pagó

Financiación
Financiación independiente
Universidad u hospital
Oregon State University
Gobierno
National Institutes of Health
Gobierno
National Cancer Institute
Gobierno
National Institute of General Medical Sciences
Gobierno
National Institute of Environmental Health Sciences
Gobierno
NCI NIH HHS
Gobierno
NIGMS NIH HHS
Gobierno
NIEHS NIH HHS
Subvenciones
National Cancer Institute (R01 CA-122906); National Cancer Institute (CA-80176); Oregon State University (P30 ES00210); National Institute of Environmental Health Sciences (ES-00-210); National Cancer Institute (R29 CA065525); National Institute of General Medical Sciences (R01 GM104977); National Institute of Environmental Health Sciences (P30ES000210); National Institute of Environmental Health Sciences (#P30-ES00210); National Cancer Institute (CA 90890); National Cancer Institute (CA-65525); National Cancer Institute (R01 CA080176); National Cancer Institute (R01 CA065525); National Cancer Institute (P01 CA090890); National Cancer Institute (R01 CA122959); National Cancer Institute (CA122959); National Cancer Institute (CA122906); National Institutes of Health (CA-65525); National Institutes of Health (CA-80176); National Institutes of Health (CA-90890); National Institutes of Health (CA122906); National Institutes of Health (#ES00210); National Institutes of Health (CA122959); National Institutes of Health (R01GM104977); National Institutes of Health (P30ES00210)

Según 8 financiadores declarados y la declaración de financiación del texto completo.

Publicación

Publicado
2014-01-22 · PLoS One · vol. 9 · número 1 · pág. e86787
Editorial
Public Library of Science
Citado
123 citas · más que el 98% de estudios similares · 7.1× el promedio de su campo
Impacto
Entre el 10 % más citado de su campo
Referencias
50 trabajos
Acceso
Acceso abierto (revista) · CC-BY
Áreas de investigación
Genomics, phytochemicals, and oxidative stress · Epigenetics and DNA Methylation · Polyamine Metabolism and Applications
Palabras clave
LNCaP, DNA methylation, Prostate cancer, Epigenetics, Cancer research, Methylation, Biology, Carcinogenesis, Cancer, Molecular biology, Gene expression, Gene, Genetics
MeSH
prostate, cells, cultured, epithelial cells, humans, prostatic neoplasms, isothiocyanates, sulfoxides, indoles, dna primers, anticarcinogenic agents, analysis of variance, chromatin immunoprecipitation, dna methylation, male, promoter regions, genetic, real-time polymerase chain reaction

9 autores

  • Carmen P. Wong🇺🇸Oregon State University
  • Anna J. C. Hsu🇺🇸Oregon State University
  • Alex Buchanan🇺🇸Oregon State University
  • Zoraya Palomera‐Sánchez🇺🇸Oregon State University
  • Laura M. Beaver🇺🇸Oregon State University
  • Eugene Andres Houseman🇺🇸Oregon State University
  • David E. J. Williams🇺🇸Oregon State University
  • Roderick H. Dashwood🇺🇸Oregon State University
  • Emily H. Ho🇺🇸 · autor de correspondenciaOregon State University

Resumen

El texto original del estudio, en el idioma en que se publicó.

Epigenetic changes, including aberrant DNA methylation, result in altered gene expression and play an important role in carcinogenesis. Phytochemicals such as sulforaphane (SFN) and 3,3'-diindolylmethane (DIM) are promising chemopreventive agents for the treatment of prostate cancer. Both have been shown to induce re-expression of genes, including tumor suppressor genes silenced in cancer cells, via modulation of epigenetic marks including DNA methylation. However, it remained unclear the effects SFN and DIM on DNA methylation at a genomic scale. The goal of this study was to determine the genome-wide effects of SFN and DIM on promoter methylation in normal prostate epithelial cells and prostate cancer cells. Both SFN and DIM treatment decreased DNA methyltransferase expression in normal prostate epithelial cells (PrEC), and androgen-dependent (LnCAP) and androgen-independent (PC3) prostate cancer cells. The effects of SFN and DIM on promoter methylation profiles in normal PrEC, LnCAP and PC3 prostate cancer cells were determined using methyl-DNA immunoprecipitation followed by genome-wide DNA methylation array. We showed widespread changes in promoter methylation patterns, including both increased and decreased methylation, in all three prostate cell lines in response to SFN or DIM treatments. In particular, SFN and DIM altered promoter methylation in distinct sets of genes in PrEC, LnCAP, and PC3 cells, but shared similar gene targets within a single cell line. We further showed that SFN and DIM reversed many of the cancer-associated methylation alterations, including aberrantly methylated genes that are dysregulated or are highly involved in cancer progression. Overall, our data suggested that both SFN and DIM are epigenetic modulators that have broad and complex effects on DNA methylation profiles in both normal and cancerous prostate epithelial cells. Results from our study may provide new insights into the epigenetic mechanisms by which SFN and DIM exert their cancer chemopreventive effects.

Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).

Confianza de la comunidad

Cargando…

¿Cuánto confías en los hallazgos de este estudio?

0 · nada10 · totalmente

Comentarios

¿Algo está mal aquí?

Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.

Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.